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Abstract 
 
Genetic and environmental determinants of skeletal phenotypes such as bone mineral density 
(BMD) may converge through the epigenome, providing a tool to better understand osteoporosis 
pathophysiology. As the epigenetics of BMD have been largely unexplored in humans, we 
performed an epigenome wide association study (EWAS) of BMD. We undertook a large-scale 
BMD EWAS using the Infinium HumanMethylation450 array to measure site-specific DNA 
methylation in up to 5,515 European descent individuals (NDiscovery = 4,614, NValidation = 901). We 
associated methylation at multiple cytosine-phosphate-guanine (CpG) sites with dual-energy X-
ray absorptiometry derived femoral neck and lumbar spine BMD. We performed sex-combined 
and stratified analyses, controlling for age, weight, smoking status, estimated white blood cell 
proportions, and random effects for relatedness and batch effects. A 5% false-discovery rate was 
used to identify CpGs associated with BMD. We identified one CpG-site, cg23196985, 
significantly associated with femoral neck BMD in 3,232 females (P = 7.9x10-11) and 4,614 
females and males (P = 3.0x10-8). cg23196985 was not associated with femoral neck BMD in an 
additional sample of 474 females (P = 0.64) and 901 males and females (P = 0.60). Lack of 
strong consistent association signal indicates that among the tested probes, no large-effect 
epigenetic changes in whole blood associated with BMD, suggesting future epigenomic studies 
of musculoskeletal traits measure DNA methylation in a different tissue with extended genome 
coverage. This article is protected by copyright. All rights reserved 
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Introduction 
 
Osteoporosis is primarily an aging-related disease characterized by compromised bone strength 
that increases the risk of fracture. Due to population ageing worldwide the incidence of 
osteoporosis is increasing, exceeding $17 billion per year in direct care costs within the United 
States of America(1) and costing upwards of €37 billion per year in the EU-27 member states.(2) 
Identifying the causes of osteoporosis will improve the understanding of its pathology, leading to 
better or more efficient treatments of this common and costly disease. Low bone mineral density 
(BMD) is one of the major risk factors for fracture, and is largely used in clinical prediction tools 
for fracture and gauging response to treatment.  Genome-wide association studies (GWAS) of 
BMD directly assessed at the femoral neck (FN) and lumbar spine (LS), the two most commonly 
measured sites for quantifying BMD and diagnosing osteoporosis, have been instrumental in 
identifying novel genetic loci influencing osteoporosis disease-risk.(3,4) However, epigenetic 
variation in the genome, which can be influenced by both genetic and environmental factors,(5,6) 
may also influence BMD, yet the epigenetic influences on BMD have largely been unexplored. 
 
One of the most stable epigenetic processes is DNA methylation, or, the addition of a CH3 
methyl group to cytosine, typically in the context of cytosine paired sequentially to a guanine 
nucleotide, separated by a phosphate group (CpG). DNA methylation is known to play a role in 
gene expression and cell differentiation(7,8) and differential DNA methylation has been linked to 
multiple human complex traits and disease phenotypes.(5,9–12) Studies performed using bone 
samples have identified epigenetic alterations that influence bone cell function.(13,14) We studied 
epigenetic variation in whole blood, as a proxy for difficult-to-acquire samples such as bone, in 
relation to BMD because epigenetic markers are often stable across multiple tissues, and immune 
cells within blood are known to influence bone homeostasis.(15) Furthermore, osteoclasts are 
derived from the monocyte-macrophage lineage found in whole blood.(16) Although epigenetic 
profiling has been performed previously in bone samples from osteoporotic and osteoarthritic 
patients(17) and an epigenome-wide association study (EWAS) of BMD has been performed in 
mice,(18) EWAS of BMD have not been reported in humans with validation of significant 
findings. 
 
We, therefore, undertook a large-scale BMD EWAS, assessing the association of up to 473,882 
CpGs quantified in whole-blood with BMD measured in up to 4,614 individuals across five 
cohorts from Europe and North America. To our knowledge, this study is the largest EWAS of a 
musculoskeletal trait performed to date. We used an additional 901 individuals as a validation 
cohort to increase the reliability of our results. 
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Methods 
 
Individual cohorts 
We performed our EWAS in cohorts comprised of European descent individuals. Cohorts used 
for the discovery analysis were the TwinsUK Registry (TUK), Framingham Study Offspring 
Cohort (FOS), Avon Longitudinal Study of Parents and Children (ALSPAC; further information 
on the ALSPAC cohorts and ARIES project is included in Supplementary Table 1), Rotterdam 
Study (RS), and the Danish Twin Registry (DTR). The cohort used for validation of significant 
findings was the Framingham Study Generation 3 cohort (Gen3), a cohort including family 
members of FOS (Table 1; Supplementary Table 1). 
 
Both, or one of, FN and LS BMD were measured in each cohort by dual-energy X-ray 
absorptiometry (DXA) (Supplementary Table 2). All cohorts, except the ALSPAC and DTR, 
followed the same methods for extracting DNA from whole-blood tissue and quantifying DNA 
methylation. Whole-blood tissue DNA was extracted using the DNeasy Blood & Tissue Kit 
(Qiagen, Inc.), followed by bisulfite conversion of 750 ng DNA using the EZ DNA Methylation 
Kit (Zymo Research) following manufacturer instructions. The ALSPAC cohort and the DTR 
cohort performed DNA extraction and conversion as described previously.(19,20) DNA 
methylation across the genome was quantified using the Infinium Human Methylation450 
BeadChip (Illumina), assaying up to 482,421 CpGs throughout the human genome. Image 
intensities were extracted using GenomeStudio Methylation Module (v1.8) software. Cohort-
specific criteria were applied in further quality control and normalization of probe intensities 
(Supplementary Table 3). 
 
Statistical analyses 
For discovery analyses, each cohort followed a pre-specified analysis plan. FN and LS BMD 
residuals were calculated by fitting a linear regression model, adjusting for age, weight, and sex. 
For sex-specific analyses, the term for sex was removed from the model. In addition, the DTR 
adjusted for birth weight discordance as historically, DTR samples were selected to address birth 
weight discordance in twins (Supplementary Table 1). To address the issue of cell heterogeneity 
in whole blood tissue, each cohort calculated the estimated white blood cell proportions of B-
cells, T-cells (CD4+ and CD8+), granulocytes, natural killer cells, and monocytes using the 
Houseman et al. method for quadratic projections.(21) DNA methylation for each probe was 
transformed to a standard normal distribution using quantile normalization. The association 
between DNA methylation and BMD was then calculated by fitting a linear mixed effects model 
for normalized DNA methylation, including BMD residuals, smoking (measured as smokers, 
non-smokers, or former-smokers), age, weight, sex, and estimated white blood cell proportions 
as fixed effects, and terms for family structure and batch effects as random effects, where 
relevant. We used BMD residuals in order to reduce problems due to collinearity between BMD, 
weight, and age when fitting our linear mixed effects model. Association testing was performed 
in male, female, and combined samples. Each cohort was assessed for epigenome-wide statistical 
inflation by calculating the genomic inflation factor lambda (λ) and generating a quantile-
quantile plot (QQ-plot). Lambda can be calculated to estimate the deviation of a distribution 
from a null expected distribution, whereas QQ-plots can be used to visualize the deviation of a 
distribution from a null expected distribution. 
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Fixed-effects meta-analyses were performed using METAL(22) for FN and LS sex-combined and 
sex-stratified analyses. We used the I2 statistic to quantify the variability in association effect 
estimates due to statistical heterogeneity, excluding probes with heterogeneous I2 statistics 
(PHet<0.05). Statistical significance, when considering the multiple testing burden, was 
determined by calculating Benjamini-Hochberg (BH) adjusted P-values for each meta-analysis. 
Probes with significant BH-adjusted P-values (PBH<0.05) would, therefore, be significant at a 
5% false-discovery rate (FDR). Summary statistics for the FN and LS sex-combined and sex-
stratified meta-analyses are available for download (www.gefos.org). 
 
Associated probes were assessed for their twin-based heritability using normalized methylation 
beta values estimated from 330 female MZ twin pairs and 34 female DZ twin pairs from the 
TUK cohort, adjusted for age, body mass index, smoking status, alcohol consumption, predicted 
whole blood cell-type counts, DNA methylation plate, and position on the plate. Heritability was 
estimated by fitting the classical ACE model in OpenMX.(23) The observed variance in the 
adjusted beta values was partitioned into additive genetic (A), common environmental (C), and 
unique environmental (E) factors. Heritability was defined as A/(A+C+E) 
 
Associated probes were assessed for the influence of single nucleotide polymorphisms (SNPs) 
that overlapped the probe body by mapping these probes to dbSNP 146.(24) This was assessed by 
adding a term for the dosage of each SNP to the discovery linear mixed effects models in cohorts 
with genotype data, to observe if the association between DNA methylation and BMD was 
influenced by the genetic polymorphism at the probe. 
 
Gen3 samples were assessed using the same methods as in the analysis of FOS samples to 
perform validation analyses of significantly associated probes. Probes were deemed robustly 
associated with BMD if they met a validation P-value of less than 0.05. These samples are not 
completely independent from the FOS samples because the Framingham Study is a family-based 
study with several cohorts, and, therefore, there is underlying family structure. 
 
To assess the power of our study, we performed 5000 permutations on the 775 TUK samples 
with FN BMD measurements. FN was randomly sampled based on the twin and family structure 
prior to fitting linear mixed effects models, and the power was defined as the number of 
permutations with P-values greater than the observed P-value for the TUK samples (P = 1.14x10-
5; Supplementary Table 8) 
 
Results 
 
Meta-analysis 
Meta-analyses of discovery cohorts identified CpG-site cg23196985 associated at a 5% FDR for 
FN sex-combined (β = 0.66, SE = 0.19, P = 2.99x10-8, PBH = 1.30x10-2) and FN female (β = 0.95, 
SE = 0.15, P = 7.86x10-11, PBH = 3.41x10-5; Figure 1; Figure 2; Table 2) analyses. CpG-site 
cg23196985 maps to the 5’ untranslated region of the liver carboxylase 1 gene (CES1), which is 
expressed in the liver and whole-blood(25), yet with no currently reported associations with BMD 
by GWAS in the same chromosomal region (16q12.2) and with the nearest BMD associated SNP 
mapping approximately 4 mega base pairs upstream at the SALL1 and CYLD locus(26). The 
calculated lambdas and QQ-plots for the meta-analyses of FN female and sex-combined analyses 
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revealed no statistical inflation of the association P-values (λfemale = 1.02, λsex-combined = 0.97; 
Supplementary Table 9). We observed no significantly associated CpG-sites with LS BMD in 
sex-combined or sex-stratified analyses (Supplementary Figures). 
 
We tested for the influence of SNPs underlying cg23196985 in females from the FOS, RS, and 
ALSPAC cohorts, as the strength of the association was stronger in females than in the sex-
combined analysis. Because some of the samples in our cohorts included twins, we first 
estimated the evidence for heritability of DNA methylation levels at cg23196985 in the TUK 
cohort. We observed evidence for additive genetic effects with a heritability estimate of 0.69 at 
cg23196985, and therefore pursued further analyses exploring the association between DNA 
methylation levels at this CpG-site and BMD conditional on SNP genotypes. All twins were 
homozygous for the reference allele at rs144950224, a SNP that maps directly to the probe’s 
target CpG-site. Four SNPs mapped to the cg23196985 50 base pair probe sequence, and these 
included rs144950224, rs12149371, rs12149373, and rs3815583. SNP rs144950224 was found to 
be rare within our cohorts, with a minor allele frequency (MAF) of approximately 0.5% in FOS 
samples, 0.1% in RS samples, and no carriers in ALSPAC samples. We observed no notable 
change in association P-values upon conditioning with each of the four SNPs (Supplementary 
Table 10).  
 
In the validation sample, cg23196985 was not associated with FN in Gen3 female (P = 0.64) and 
sex-combined (P = 0.60) analyses. However, after meta-analyzing Gen3 validation data with 
discovery results, the probe remained strongly associated in female-only analyses (β = 0.86, SE = 
0.14, P = 3.7x10-10; N = 4,345) but not in sex-combined analysis (P = 0.68, N=5,301). 
 
For our power calculation, we found all permutations were less significant than our observed P-
value for the 775 TUK samples at P = 1.14x10-5 (permuted P-value range: 0.99 to 2.46x10-5), this 
suggested we had 100% power to detect the observed effect size (β = 1.20, SE = 0.27) between 
bone density measurements and methylation at cg23196985 in CES1. 
 
Individual cohorts 
Individual cohort analyses identified seven probes that were significantly associated in two 
cohorts with sex-combined or sex-stratified analyses (Supplementary Table 4), but there were no 
other cohort-specific significant associations. The DTR LS female analysis identified four 
significantly associated probes, two of which map to genes, cg04081651 (MAP3K8), 
cg09832237, cg14793931 (ZFR2), and cg24029028 (Supplementary Table 5). The DTR LS male 
analysis identified one significantly associated probe, cg23214071 (HLA-DQB1) (Supplementary 
Table 6). The TUK LS female analysis identified two significantly associated probes, 
cg24117468 (P4HA2) and cg02526790 (TG) (Supplementary Table 7). The calculated lambda 
and QQ-plot for the DTR LS female analysis revealed statistical inflation of the association P-
values (λ = 1.46), but the lambda and QQ-plots for the remainder of the cohorts showed no large 
inflation or deflation of association P-values (Supplementary Table 9). 
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Discussion 
 
In the first large-scale assessment of the contribution of epigenetic changes in whole blood to 
BMD we did not identify methylation changes reliably associated with this clinically relevant 
trait. CpG-site cg23196985 was found in the discovery meta-analysis to be strongly associated 
with FN BMD in females-only and in analyses combining males and females, but upon 
validation in an extended sample which included related individuals, the association was 
attenuated in the female analysis and completely absent in sex-combined analyses. 
 
These findings provide important insights into the field of epigenetics. The first, is that using a 
precisely measured trait, BMD, which is highly heritable with estimates from 50–85%(27) and for 
which genetic determinants have been identified through GWAS,(3,4,27) there do not appear to be 
associations between methylation changes and BMD. While whole blood methylation changes 
may not be the ideal tissue within which to test epigenetic influences on bone, this conveniently 
accessible tissue has many links to bone biology, including the fact that osteoclasts and 
monocyte/macrophages originate from the same precursors.(15,16) The extent to which 
methylation changes are shared between bone and whole blood is not well known. However, 
evidence shows that a significant proportion of methylation variation genome-wide can be 
conserved across tissues.(28) Additional explanations for our mostly null findings include the 
possibility that DNA methylation changes may not have a large influence on BMD. 
 
Notwithstanding the general lack of consistent associations with BMD across the genome, we 
did generate evidence for suggestive association of cg23196985 with FN BMD in females. 
However, we caution that these findings require further replication. Since we are unaware of any 
available replication data to test this hypothesis, these findings will require replication in future 
studies.  
 
There is limited evidence for the effects of DNA methylation on bone. A methylation profiling 
study that compared the differences between bone samples of 27 osteoporotic and 23 
osteoarthritic patients was undertaken on an earlier DNA methylation platform, the 
HumanMethylation27 BeadChip (assessing approximately 27,000 CpGs in the genome), and 
were able to identify bone genes following pathway analyses of over 200 differentially 
methylated CpGs, however, to date, these results lack replication.(17) Another study failed to 
demonstrate specific effects of DNA methylation, assessed by sequencing methods, on RANKL 
in the bones of patients with osteoporotic fractures.(29) The evidence from previous studies and 
our own suggests that if strong effects of DNA methylation on bone biology are to be identified, 
they may not be detectable with current analytical approaches. 
 
A strength of our study was the sample size, and a conservative estimate of statistical power to 
identify epigenetic effects on BMD that account for 0.8% of its variance. The large sample size 
also allowed us to classify several cohort-level associations were likely to be false positives. For 
example, TUK female analyses identified two probes significantly associated with LS BMD, but 
this association was not observed in any other cohort, suggesting the associations were false 
positives (Supplementary Table 4; Supplementary Table 5).  
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One of the key limitations of cohort-based epigenetic studies is the lack of cell-sorted data for 
analysis. As discussed by Birney et al.,(30) optimal planning at the outset of a study is ideal, 
however, such coordination is difficult to implement in large cohorts and so bioinformatics 
methods must be applied post hoc to adjust for suboptimal study designs. We adjusted for cell 
heterogeneity within whole blood, and therefore the signal we tested for association with BMD 
would be ubiquitous within whole blood. Such ubiquitous signals within whole blood may only 
be detectable for extremely strong environmental modifiers of DNA methylation, such as 
cigarette smoking.(5,6) Targeted EWAS of specific cell types within whole blood with clear roles 
in bone biology, such as monocytes due to their role in osteoclastogenesis, may be more fruitful. 
Furthermore, longitudinal studies can identify disease-risk biomarkers and provide mechanistic 
insights, however, these are generally underpowered when studying BMD due to the relatively 
small changes in BMD that occur over time. As we have shown that large-scale whole blood 
EWAS of BMD does not identify disease-risk biomarkers for osteoporosis risk, a well-powered 
longitudinal study with a wide-range of time points and bone samples may be more informative. 
 
In the largest EWAS meta-analysis to date of BMD, we observed a probe near CES1 to be 
associated with FN BMD in the discovery sample of up to 4,826 individuals, but not with the 
same phenotype in a semi-independent validation sample of 901 individuals. In conclusion, these 
findings suggest that there are no large effects of methylation changes on BMD in whole blood 
in the epigenome, which are common and well captured by the Infinium HumanMethylation450 
BeadChip. 
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Figure Legends 
 
Figure 1. Quantile-quantile plots (QQ-plots) of the distribution of observed -log10 association 
P-values against the expected null distribution, for discovery meta-analyses of FN BMD in (a) 
females-only and (b) sex-combined analyses. Genomic inflation lambda scores are given in each 
QQ-plot, to quantify statistical inflation of P-values. No evidence for inflation was observed in 
the QQ-plots or as calculated by lambda scores. 
 
Figure 2. Manhattan plots of -log10 association P-values for discovery meta-analyses of FN 
BMD in (a) females-only and (b) sex-combined analyses. 
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Tables 
 
Table 1. Sample Sizes of Discovery and Replication Cohorts. 
                
Phase Cohort 
Sample Size 
FN BMD LS BMD 
Pooled Females Males Pooled Females Males 
Discovery 
Avon Longitudinal Study of Parents and Children (ALSPAC) 715 715 0 0 0 0 
Danish Twin Registry (DTR) 267 132 135 260 132 128 
Framingham Study Offspring Cohort (FOS) 2207 1254 953 2203 1259 953 
Rotterdam Study (RS) 650 356 294 633 346 287 
TwinsUK (TUK) 775 775 0 770 770 0 
Discovery Total 4614 3232 1382 3866 2507 1368 
Validation 
FOS Gen3 901 448 453 0 0 0 
Discovery + Validation Total 5515 3680 1835 3866 2507 1368 
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Table 2. Meta-Analysis Results for Association of cg23196985 with FN BMD in Both Female 
(Top Row) and Sex-Pooled (Bottom Row) Analyses in Discovery phase, with Replication and 
Combined Discovery and Replication Analyses. 
 
Discovery Validation Combined 
β SE P PBH PHet β SE P β SE P PHet 
0.95 0.15 7.9E-11 3.4E-05 0.81 0.19 0.39 0.64 0.86 0.14 3.8E-10 0.43 
0.66 0.12 3.0E-08 1.3E-02 0.1 -0.01 0.02 0.6 0.01 0.02 0.68 3.0E-07 
β = effect size; SE = standard error; PBH = Benjamini-Hochberg adjusted P-value; I2 = heterogeneity measure;  
PHet = heterogeneity P-value 
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